Aptus Pharma IPO Details
| Detail | Description |
|---|---|
| IPO Date | September 23, 2025 to September 25, 2025 |
| Listing Date | [.] |
| Face Value | ₹ 10 per share |
| Issue Price Band | ₹ 65 to ₹ 70 per share |
| Lot Size | 2,000 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 18,60,000 shares (aggregating up to ₹ 13.02 Cr) |
| Reserved for Market Maker | 94,000 shares (aggregating up to ₹ 0.6580 Cr) Market-Hub Stock Broking Pvt.Ltd. |
| Net Offered to Public | 17,66,000 shares (aggregating up to ₹ 12.36 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Share Holding Pre Issue | 50,00,000 shares |
| Share Holding Post Issue | 68,60,000 shares |
About Aptus Pharma IPO
Aptus Pharma Ltd is launching its SME IPO from September 23 to 25, 2025, with shares priced between ₹65 and ₹70 each. The Aptus Pharma IPO size is ₹13.02 crore through a fresh issue of approximately 18,60,000 shares. The minimum lot size is 2,000 shares, requiring an investment of about ₹1.3 lakh. The IPO will list on BSE SME, with allotment scheduled for September 26, 2025, refunds starting September 29, and listing expected on September 30, 2025.
Company Background
Aptus Pharma, established in 2010 and headquartered in Gujarat, markets a wide range of pharmaceutical products across multiple therapeutic areas. The company does not own manufacturing units but works with contract manufacturers to supply formulations in several categories, like anti-infectives, gastrointestinal, anti-allergic, nutritional supplements, and more. It serves diverse healthcare professionals, including general practitioners and specialists.
Operations And Product Range
Facility And Production
Aptus Pharma operates on a contract manufacturing model, sourcing products from seven reputed manufacturers. The company focuses on marketing, sales, and distribution while ensuring quality through strict vendor selection and control processes. Its supply chain is supported by strong distributor and stockist networks.
Brands And Market Presence
The Aptus Pharma IPO company’s brands are widely recognised in the healthcare segment due to their presence across multiple therapy areas. Its products reach customers mainly through pharma distributors and retailers across India, supported by a robust sales and marketing infrastructure, which includes a dedicated field force catering to healthcare professionals.
Revenue Channels
- • Marketing and sales of pharmaceutical formulations across diverse therapy categories.
- • Contract manufacturing partnerships with seven manufacturing units.
- • Distribution through a network of stockists and wholesalers across India.
- • Sales to hospitals, clinics, and pharmacies catering to various medical specialists.
Management And Shareholding
Promoters And Shareholding
The promoters of Aptus Pharma IPO hold significant stakes and are actively involved in the company’s strategic and operational decisions. The promoter group includes experienced professionals from the pharmaceutical domain who guide the company’s growth and compliance frameworks. The IPO will dilute the promoter’s stake, broadening the company’s equity base while ensuring promoter control remains.
Board Members
The board of directors comprises the promoter directors along with independent professionals who oversee audit, governance, risk management, and compliance matters. This mix ensures transparency, accountability, and strategic guidance necessary for a growing pharmaceutical marketer preparing for expanded visibility in public markets.
IPO Objectives
- • Raise working capital to support increased inventory and distribution reach.
- • Strengthen marketing and sales efforts to expand market share in therapeutic segments.
- • Enhance corporate infrastructure, governance, and systems for compliance.
- • General corporate purposes to support operational and strategic growth.
Conclusion
Aptus Pharma IPO offers investors an opportunity to invest in a fast-growing pharmaceutical marketing company with a diversified product range and established B2B relationships. The company’s asset-light business model and strong financial performance underscore its potential for scale. The IPO proceeds will help accelerate growth, enhance market presence, and improve operational efficiencies.
Aptus Pharma IPO Financial Information
Latest Revenue
24.64
₹ Crore
Profit After Tax
3.1
₹ Crore
Net Worth
6.97
₹ Crore
Total Borrowing
10.36
₹ Crore
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Total Borrowing | ||||
|---|---|---|---|---|---|---|---|---|---|
| 31 Mar 2025 | 21.92 | 24.64 | 3.1 | 6.97 | 10.36 | ||||
| 31 Mar 2024 | 10 | 18 | 1 | 2 | 5 | ||||
| 31 Mar 2023 | 6.22 | 13.90 | 0.19 | 0.97 | 2.21 | ||||
| Amount in ₹ Crore | |||||||||
Aptus Pharma Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 44.50% |
| ROCE | 45.66% |
| Debt/Equity | 1.49 |
| RoNW | 44.50% |
| EBITDA Margin | 19.31% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 6.2 | 5 |
| P/E (x) | 11.29 | 15 |
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
Raise working capital to support increased inventory and distribution reach.
Strengthen marketing and sales efforts to expand market share in therapeutic segments.
Enhance corporate infrastructure, governance, and systems for compliance
General corporate purposes to support operational and strategic growth.
Download regulatory filings
Aptus Pharma IPO Timeline
| IPO Open Date | Tue, Sep 23, 2025 |
| IPO Close Date | Thu, Sep 25, 2025 |
| Tentative Allotment | Fri, Sep 26, 2025 |
| Initiation of Refunds | Mon, Sep 29, 2025 |
| Credit of Shares to Demat | Mon, Sep 29, 2025 |
| Tentative Listing Date | Tue, Sep 30, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Thu, Sep 25, 2025 |
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 4,000 | ₹2,80,000 |
| Individual investors (Retail) (Max) | 2 | 4,000 | ₹2,80,000 |
| S-HNI (Min) | 3 | 6,000 | ₹4,20,000 |
| S-HNI (Max) | 7 | 14,000 | ₹9,80,000 |
| B-HNI (Min) | 8 | 16,000 | ₹11,20,000 |